According to a new report, published by KBV research, The Global Epigenetics Market size is expected to reach $2.9 billion by 2028, rising at a market growth of 14.6% CAGR during the forecast period.
The Non Oncology segment is showcasing a CAGR of 16.6% during (2022 - 2028). This can be attributed to private institutions and biopharmaceutical companies' aggressive R&D endeavors for the identification of epigenetic markers linked to various illnesses. Several non-oncology conditions, like metabolic disorders, neurological disorders, and viral diseases, have been linked to epigenetic alterations. Private institutions and biopharmaceutical businesses conduct extensive research to identify biomarkers for drug development.
The Kits segment acquired maximum revenue share in the Global Epigenetics Market by Product in 2021, thereby, achieving a market value of $1.29 billion by 2028. This is due to the increased availability and usage of epigenetic kits, which are known for their high sensitivity and quick results. Many biotechnology businesses produce ready-to-use kits for the detection of epigenetic changes. Kits for nucleic acid purification, DNA methylation status analysis, and detection of histone modifications by various enzymes are all available on the market, as are kits for chromatin immunoprecipitation. Epigenetic diagnostic kits are used to diagnose illnesses caused by epigenetic alterations in the early phases of treatment and to monitor therapeutic efficacy. They operate on the basis of immunoprecipitation with the help of modified monoclonal antibodies.
The Contract Research Organizations segment has shown growth rate of 16.3% during (2022 - 2028). This is due to increased investment in R&D projects, a preference for outsourcing activities due to time and cost restrictions, and patent expiration in the healthcare industry. Contractt research outsourcing collaborations provide cutting-edge services, therefore government agencies prefer to Contractt projects to CROs, allowing the market to develop.
The North America is the fastest growing region in the Global Epigenetics Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1.0 billion by 2028. The Europe market is estimated to witness a CAGR of 14.1% during (2022 - 2028). Additionally, The Asia Pacific market would exhibit a CAGR of 15.2% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/epigenetics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Abcam plc, Agilent Technologies, Inc., Hologic, Inc., Illumina, Inc., Merck Group, PerkinElmer, Inc., Qiagen N.V., Thermo Fisher Scientific, Inc., Zymo Research, and Active Motif, Inc.
By Application
By Product
By End User
By Geography
Companies Profiled
Unique Offerings 
